Broker Research
November 06, 2025 / 11:13 IST
Reported Consolidated quarterly numbers for Piramal Pharma are:Net Sales at Rs 2,043.72 crore in September 2025 down 8.83% from Rs. 2,241.75 crore in September 2024.
Story continues below Advertisement
Quarterly Net Loss at Rs. 99.22 crore in September 2025 down 539.22% from Rs. 22.59 crore in September 2024.
EBITDA stands at Rs. 224.29 crore in September 2025 down 44.31% from Rs. 402.72 crore in September 2024.
Piramal Pharma shares closed at 200.42 on November 03, 2025 (NSE)
| Piramal Pharma | | Consolidated Quarterly Results | in Rs. Cr. |
|
| Sep'25 | Jun'25 | Sep'24 | | Net Sales/Income from operations | 2,043.72 | 1,933.71 | 2,241.75 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 2,043.72 | 1,933.71 | 2,241.75 | | EXPENDITURE | | Consumption of Raw Materials | 483.42 | 524.35 | 575.14 | | Purchase of Traded Goods | 374.83 | 342.83 | 394.77 | | Increase/Decrease in Stocks | -155.75 | -173.13 | -173.44 | | Power & Fuel | -- | -- | -- | | Employees Cost | 611.46 | 618.59 | 559.53 | | Depreciation | 202.84 | 197.28 | 192.22 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 571.07 | 514.37 | 544.14 | | P/L Before Other Inc., Int., Excpt. Items & Tax | -44.15 | -90.58 | 149.39 | | Other Income | 65.60 | 58.40 | 61.11 | | P/L Before Int., Excpt. Items & Tax | 21.45 | -32.18 | 210.50 | | Interest | 82.42 | 86.15 | 107.64 | | P/L Before Exceptional Items & Tax | -60.97 | -118.33 | 102.86 | | Exceptional Items | -- | 20.74 | -- | | P/L Before Tax | -60.97 | -97.59 | 102.86 | | Tax | 53.04 | 2.68 | 97.53 | | P/L After Tax from Ordinary Activities | -114.01 | -100.27 | 5.33 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | -114.01 | -100.27 | 5.33 | | Minority Interest | -- | -- | -- | | Share Of P/L Of Associates | 14.79 | 18.57 | 17.26 | | Net P/L After M.I & Associates | -99.22 | -81.70 | 22.59 | | Equity Share Capital | 1,325.52 | 1,324.82 | 1,323.14 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | -0.75 | -0.62 | 0.17 | | Diluted EPS | -0.75 | -0.62 | 0.17 | | EPS After Extra Ordinary | | Basic EPS | -0.75 | -0.62 | 0.17 | | Diluted EPS | -0.75 | -0.62 | 0.17 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
